{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Léiomyosarcome : Questions médicales les plus fréquentes",
"headline": "Léiomyosarcome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Léiomyosarcome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-08",
"dateModified": "2025-03-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Léiomyosarcome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sarcomes",
"url": "https://questionsmedicales.fr/mesh/D012509",
"about": {
"@type": "MedicalCondition",
"name": "Sarcomes",
"code": {
"@type": "MedicalCode",
"code": "D012509",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.450.795"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Léiomyosarcome",
"alternateName": "Leiomyosarcoma",
"code": {
"@type": "MedicalCode",
"code": "D007890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Emily Z Keung",
"url": "https://questionsmedicales.fr/author/Emily%20Z%20Keung",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA."
}
},
{
"@type": "Person",
"name": "Anupama Bahadur",
"url": "https://questionsmedicales.fr/author/Anupama%20Bahadur",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Rajlaxmi Mundhra",
"url": "https://questionsmedicales.fr/author/Rajlaxmi%20Mundhra",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Anoosha K Ravi",
"url": "https://questionsmedicales.fr/author/Anoosha%20K%20Ravi",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
},
{
"@type": "Person",
"name": "Poonam Gill",
"url": "https://questionsmedicales.fr/author/Poonam%20Gill",
"affiliation": {
"@type": "Organization",
"name": "Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37164640",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1124/pharmrev.122.000600"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endocannabinoid hydrolases differentially distribute in platelets and red blood cells and are differentially released by thrombin.",
"datePublished": "2022-11-11",
"url": "https://questionsmedicales.fr/article/36372184",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prostaglandins.2022.106692"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endocannabinoid release at ventral hippocampal-amygdala synapses regulates stress-induced behavioral adaptation.",
"datePublished": "2023-09-12",
"url": "https://questionsmedicales.fr/article/37703881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.celrep.2023.113027"
}
},
{
"@type": "ScholarlyArticle",
"name": "The peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis.",
"datePublished": "2023-07-07",
"url": "https://questionsmedicales.fr/article/37337838",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15930"
}
},
{
"@type": "ScholarlyArticle",
"name": "Altered mucosal and plasma polyunsaturated fatty acids, oxylipins, and endocannabinoids profiles in Crohn's disease.",
"datePublished": "2023-05-04",
"url": "https://questionsmedicales.fr/article/37149256",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prostaglandins.2023.106741"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du tissu conjonctif et des tissus mous",
"item": "https://questionsmedicales.fr/mesh/D018204"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sarcomes",
"item": "https://questionsmedicales.fr/mesh/D012509"
},
{
"@type": "ListItem",
"position": 6,
"name": "Léiomyosarcome",
"item": "https://questionsmedicales.fr/mesh/D007890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Léiomyosarcome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Léiomyosarcome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Léiomyosarcome",
"description": "Comment diagnostique-t-on un léiomyosarcome ?\nQuels examens d'imagerie sont utilisés ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels marqueurs tumoraux sont associés ?\nPeut-on confondre le léiomyosarcome avec d'autres tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endocannabinoids&page=8#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Léiomyosarcome",
"description": "Quels sont les symptômes courants du léiomyosarcome ?\nLe léiomyosarcome provoque-t-il une perte de poids ?\nPeut-on avoir des symptômes respiratoires ?\nLes symptômes varient-ils selon la localisation ?\nY a-t-il des symptômes spécifiques aux femmes ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endocannabinoids&page=8#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Léiomyosarcome",
"description": "Peut-on prévenir le léiomyosarcome ?\nLes facteurs environnementaux jouent-ils un rôle ?\nY a-t-il des habitudes à éviter ?\nLes antécédents familiaux influencent-ils le risque ?\nLe suivi médical régulier est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endocannabinoids&page=8#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Léiomyosarcome",
"description": "Quels traitements sont disponibles pour le léiomyosarcome ?\nLa chirurgie est-elle toujours nécessaire ?\nLa chimiothérapie est-elle efficace ?\nLa radiothérapie est-elle une option ?\nY a-t-il des traitements expérimentaux ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endocannabinoids&page=8#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Léiomyosarcome",
"description": "Quelles complications peuvent survenir ?\nLe léiomyosarcome peut-il se propager ?\nY a-t-il des risques liés aux traitements ?\nComment gérer la douleur liée au léiomyosarcome ?\nLe suivi post-traitement est-il crucial ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endocannabinoids&page=8#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Léiomyosarcome",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de léiomyosarcome ?\nLes maladies génétiques sont-elles un facteur ?\nLe sexe joue-t-il un rôle dans le risque ?\nL'obésité est-elle un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D007890?mesh_terms=Endocannabinoids&page=8#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un léiomyosarcome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie médicale et la biopsie des tissus affectés."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les IRM et les tomodensitométries (CT) sont couramment utilisés pour visualiser la tumeur."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie est essentielle pour confirmer la nature maligne de la tumeur."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont associés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des tests génétiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Peut-on confondre le léiomyosarcome avec d'autres tumeurs ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec d'autres sarcomes ou tumeurs musculaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du léiomyosarcome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs, des masses visibles et des troubles fonctionnels selon la localisation."
}
},
{
"@type": "Question",
"name": "Le léiomyosarcome provoque-t-il une perte de poids ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut survenir en raison de la maladie avancée."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, si la tumeur se développe dans les poumons, des symptômes respiratoires peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon la localisation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent de l'emplacement de la tumeur dans le corps."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à des tumeurs utérines, comme des saignements."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le léiomyosarcome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et l'exposition à des agents cancérigènes peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque de léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier peut aider à détecter précocement des anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le léiomyosarcome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent nécessaire pour retirer la tumeur, selon sa taille et son emplacement."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie peut être utilisée, mais son efficacité varie selon les cas."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter les tumeurs inopérables ou résiduelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques peuvent proposer des traitements expérimentaux pour le léiomyosarcome."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la métastase, la douleur chronique et des problèmes fonctionnels."
}
},
{
"@type": "Question",
"name": "Le léiomyosarcome peut-il se propager ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut se propager à d'autres organes, notamment les poumons et le foie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques liés aux traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires comme la fatigue et des nausées."
}
},
{
"@type": "Question",
"name": "Comment gérer la douleur liée au léiomyosarcome ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion de la douleur peut inclure des médicaments, la physiothérapie et des soins palliatifs."
}
},
{
"@type": "Question",
"name": "Le suivi post-traitement est-il crucial ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les récidives et gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition à des radiations, des produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de léiomyosarcome ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, touchant souvent les adultes d'âge moyen."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques sont-elles un facteur ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques, comme le syndrome de Li-Fraumeni, augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont légèrement plus susceptibles de développer un léiomyosarcome utérin."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut être associée à un risque accru de certains types de sarcomes, y compris le léiomyosarcome."
}
}
]
}
]
}
The cannabis derivative marijuana is the most widely used recreational drug in the Western world and is consumed by an estimated 83 million individuals (∼3% of the world population). In recent years, ...
Plasma levels of the major endocannabinoids 2-arachidonoylgycerol (2AG) and anandamide (N-arachidonoylethanolamine, AEA) have been identified to vary independently with particular pathological conditi...
In this study, we have quantified these enzyme activities in the major blood fractions....
In blood fractions from human volunteers, radiometric assays were used to quantify monoacylglycerol lipase and fatty acid amide hydrolase. Tagging with fluorophosphonate-rhodamine allowed quantificati...
Fatty acid amide hydrolase activity was highest in platelets, while MAGL activity was most abundant in erythrocytes. Sampling the blood of donors on two further occasions 15 days apart showed no signi...
These investigations suggest a potential role for FAAH in regulation of coagulation, while the role of MAGL in blood requires further investigation....
The endocannabinoid (eCB) system is a key modulator of glutamate release within limbic neurocircuitry and thus heavily modulates stress responsivity and adaptation. The ventral hippocampus (vHPC)-baso...
The endocannabinoid system (ECS) has been found altered in patients with multiple sclerosis (MS). However, whether the ECS alteration is present in the early stage of MS remains unknown. First, we aim...
Whole blood gene expression of ECS components and levels of endocannabinoids in plasma were measured by real-time quantitative polymerase chain reaction and ultra-high-pressure liquid chromatography-m...
No differences were found in the gene expression or plasma levels of the selected ECS components between newly diagnosed MS patients and HCs. Interferon-γ, encoded by the gene IFNG, correlated positiv...
We found no alteration in the peripheral ECS between untreated patients with MS and HC. Furthermore, our results indicate that the ECS has a minor overall involvement in the early stage of MS on infla...
Selected mucosal and plasma polyunsaturated fatty acids (PUFAs) and related oxylipins and endocannabinoids were determined in 28 Crohn's disease (CD) patients and 39 controls. Fasting blood and coloni...
The role of the Endocannabinoids (ECs) in insulin resistance, and their association with visceral obesity and metabolic profile have been studied extensively. Since the association between ECs and met...
The present case-control study was conducted among 96 singleton pregnant women aged 18-40 years, including 48 healthy pregnant women (control group) and 48 women with a positive diagnosis of GDM (case...
AEA was significantly associated with increased risk of GDM in models 1, 2 and 3 (OR = 1.22, 95% CI: 1.06-1.41; OR = 1.54, 95% CI: 1.19-1.97; OR = 1.46, 95% CI:1.11-1.91). A positive but no significan...
Our findings showed that levels of ECs were significantly higher in pregnant women with GDM compared to healthy ones. Also, ECs levels were associated with the likelihood of GDM, independent of BMI an...
Contextual drug-associated memory precipitates craving and relapse in substance users, and the risk of relapse is a major challenge in the treatment of substance use disorders. Thus, understanding the...
We applied behavioural, pharmacological and biochemical methods to detect cocaine-associated memory formation, eCBs in the dorsal dentate gyrus (dDG), and the activity of related enzymes. We further e...
In the present study, we found that cocaine induced a decrease in the level of FAAH in the dDG and increased the level of AEA. A high level of AEA activated cannabinoid type 1 receptors (CB1Rs) and fu...
Together, our findings demonstrate that the lipase FAAH influences CB1R signalling activation and granule neuron dendritic structure alteration in the dDG by regulating AEA levels and that AEA and AEA...
Cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes involved in the biosynthesis and degradation of the endocannabinoids make up the endocannabinoid system (ECS). The co...
Seizures and epilepsy are some of the most common serious neurological disorders, with approximately 80% of patients living in developing/underdeveloped countries. However, about one in three patients...
Dysregulation of hippocampus glutamatergic neurotransmission and reductions in hippocampal volume have been associated with psychiatric disorders. The endocannabinoid system modulates glutamate neurot...